IRulya Therapeutics Inc (IRLA)

Currency in USD
33.375
+0.145(+0.44%)
Real-time Data·
IRLA is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
31.93534.325
52 wk Range
3.660909.980
Key Statistics
Prev. Close
33.23
Open
32.2
Day's Range
31.935-34.325
52 wk Range
3.66-909.98
Volume
6.38K
Average Volume (3m)
30.48K
1-Year Change
-91.3536%
Book Value / Share
-36.12
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
IRLA Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
75.000
Upside
+124.72%
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash

IRulya Therapeutics Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy

Analyst Ratings

8 Buy
1 Hold
0 Sell
Ratings:
9 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 75.000
(+124.72% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Raymond James
Buy72.00+115.73%-New CoverageOct 09, 2026
Citizens
Buy77.00+130.71%-MaintainSep 29, 2026
Rodman & Renshaw
Buy70.00+109.74%-New CoverageSep 24, 2026
Citizens
Buy77.00+130.71%-UpgradeSep 22, 2026
Craig-Hallum
Buy68.00+103.75%-New CoverageAug 20, 2026

Earnings

Latest Release
Aug 14, 2026
EPS / Forecast
-12.31 / -9.40
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

IRLA Income Statement

Compare IRLA to Peers and Sector

Metrics to compare
IRLA
Peers
Sector
Relationship
P/E Ratio
−0.4x−1.6x−0.3x
PEG Ratio
0.00−0.010.00
Price/Book
−1.0x1.7x2.6x
Price / LTM Sales
-3.5x2.9x
Upside (Analyst Target)
125.7%311.9%64.3%
Fair Value Upside
Unlock19.4%9.9%Unlock

IRulya Therapeutics Inc., a biotechnology company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company’s lead asset candidature comprises eDSP, which is in Phase 3, for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient’s own red blood cells, as well as consist of an automated equipment the RCL, a sterile single-use consumable treatment kit comprising kit medical devices, syringe kit, and process solutions. IRulya Therapeutics Inc. was formerly known as Quince Therapeutics, Inc. and changed its name to IRulya Therapeutics Inc. in October 2026. The company was incorporated in 2012 and is headquartered in South San Francisco, California.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
23.52K2.31%705.60K
Other Institutional Investors
527.01K51.82%15.81M
Public Companies & Retail Investors
466.53K45.87%14.00M
Total
1.02M100.00%30.51M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Ikarian Healthcare Master Fund, L.P.9.02%91,7892,754
Ikarian Capital, LLC9.02%91,7892,754

People Also Watch

6.790
CAPR
-6.60%
6.2004
TNXP
-3.42%
19.070
AMRX
-0.94%
17.25
SRPT
-3.04%
2.8249
TNON
-2.92%

FAQ

What Is the IRulya (IRLA) Stock Price Today?

The IRulya stock price today is 33.375 USD.

What Stock Exchange Does IRulya Trade On?

IRulya is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for IRulya?

The stock symbol for IRulya is "IRLA."

What Is the IRulya Market Cap?

As of today, IRulya market cap is 33.940M USD.

What Is IRulya's Earnings Per Share (TTM)?

The IRulya EPS (TTM) is -51.81.

When Is the Next IRulya Earnings Date?

IRulya will release its next earnings report on Nov 18, 2026.

From a Technical Analysis Perspective, Is IRLA a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has IRulya Stock Split?

IRulya has split 2 times.

How Many Employees Does IRulya Have?

IRulya has 38 employees.

What is the current trading status of IRulya (IRLA)?

As of Oct 16, 2026, IRulya (IRLA) is trading at a price of 33.375 USD, with a previous close of 33.230 USD. The stock has fluctuated within a day range of 31.935 USD to 34.325 USD, while its 52-week range spans from 3.660 USD to 909.980 USD.

What Is IRulya (IRLA) Price Target According to Analysts?

The average 12-month price target for IRulya is 75.000 USD, with a high estimate of 98 USD and a low estimate of 65 USD. 8 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +124.72% Upside potential.

What Is the IRLA Premarket Price?

IRLA's last pre-market stock price is 29.920 USD. The pre-market share volume is 140.000, and the stock has decreased by -3.310, or -9.960%.

What Is the IRLA After Hours Price?

IRLA's last after hours stock price is 28.010 USD, the stock has decreased by -5.220, or -15.710%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.